Abeona Therapeutics Inc. · NASDAQ:ABEO

Abeona Therapeutics — Investor Presentation (April 2018)

34 slides from Abeona Therapeutics's investor presentation, April 2018

  1. Slide 1: Investor Presentation April 2018

    Investor Presentation April 2018 Nasdaq: ABEO

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the company, the market opportunit

  3. Slide 3: Rare Disease Pipeline

    Rare Disease Pipeline o a So a < re wu = > @ ° at re) ree < = w ate E B -] 0 | neater RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) FE B-2 0] ssvsueovr EPIDERMOLYSIS BULLOSA (£8) A 3) O ~ ] 0 2 senav-s0sH SANFILIPPO SYNDROME TYPE A (MPS ||/A) ABO-101 iiss SANFILIPPO SYNDROME TYPE B (MPS |B) ABO-

  4. Slide 4: Global Approach to Development

    Global Approach to Development Global Clinical Trials • MPS IIIA: US, EU & Australia Nationwide Children’s Hospital • MPS IIIB: US & EU ABO-102, ABO-101 • RDEB: US • Batten: US & EU (2018) • Supportive Natural History Studies Stanford University Hamburg-Eppendorf EB-101 ABO-201, ABO-202 Clinico de S

  5. Slide 5: EB-101 Recessive Dystrophic Epidermolysis Bullosa

    EB–101 Recessive Dystrophic Epidermolysis Bullosa 2018 Pivotal Phase 3 for Breakthrough Therapy in severe form of EB Orphan Drug Orphan Drug Rare Pediatric Fast Track Designation (FDA) Designation (EU) Disease Designation (FDA) Designation (FDA) Breakthrough Therapy Regenerative Medicine 5 Designati

  6. Slide 6: EB-101 for Severe Form of Epidermolysis Bullosa

    EB-101 for Severe Form of Epidermolysis Bullosa • Group of devastating inherited connective tissue diseases; characterized by skin blisters and erosions ⁻ Recessive Dystrophic Epidermolysis Bullosa (RDEB) - absence of the COL7A1 gene (encodes type VII collagen to anchor skin to the underlying stroma

  7. Slide 7: Supportive Natural History Study

    Supportive Natural History Study 128 RDEB Subjects - Clinical Trial Readiness • Multi-year Enrollment complete: - 1,436 wounds (1,041 recurrent wounds/395 chronic open wounds) • 100% of patients reported a history of either chronic open wounds or recurrent wounds with no healing > 12 weeks • Demonst

  8. Slide 8: EB-101 – Autologous Gene Therapy

    EB-101 – Autologous Gene Therapy EB-101: Ex-vivo Cell Therapy - gene therapy EB-101: gene-corrected skin treatment correction of patient cells to replace COL7A1 cDNA EB-101 ready for application 8

  9. Slide 9: EB-101 Case Study

    EB-101 Case Study Baseline 3 months 6 months 12 months 24 months 24 months Anti-K1 Pab Anti-COl7A1 NC2 Mab Hoechst 33342 Anti-K14 Pab Anti-COl7A1 NC2 Mab Hoechst 33342 Anti-COl7A1 NC2 Mab Anti-COl7A1 NC2 Mab Anti-COl7A1 NC1 Pab Anti-COl7A1 NC1 Pab Anti-COl7A1 NC1 Pab Hoechst 33342 Hoechst 33342 Hoec

  10. Slide 10: Summary of Completed Phase 1/2 Trial Results

    Summary of Completed Phase 1/2 Trial Results Wound Healing Treated Wounds v. Untreated Control Phase 1/2 Patient Reported Outcomes Wounds Global Rating Scale (PROs) Pre- 3 Month 6 Month 9 Month 12 Month Grafting Presence of pain at 58.3% 0% 16.7% 20% 0% wound site (% reported yes) Itch at wound site

  11. Slide 11: ABO-102 / ABO-101 MPS III Clinical Programs

    ABO-102 ABO-101 MPS III Clinical Programs Ongoing global Phase 1/2 clinical trials for rare lysosomal storage diseases Rare Pediatric Orphan Drug Orphan Drug Disease Designation (FDA) Designation (EU) Designation (FDA) Regenerative Medicine Fast Track 11 Advanced Therapy *ABO-102 Designation (FDA)*

  12. Slide 12: Sanfilippo Syndrome (MPS III)

    Sanfilippo Syndrome (MPS III) Sanfilippo syndromes (MPS IIIA & IIIB) are inherited monogenic disorders that cause lysosomal enzyme deficiency • Two most common forms, each categorized by a deficient enzyme: Normal cell - MPS IIIA (SGSH) - MPS IIIB (NAGLU) • Abnormal accumulation of glycosaminoglycan

  13. Slide 13: MPS III Natural History Study

    MPS III Natural History Study • Enrollment complete: 25 subjects, 15 MPS IIIA & 10 MPS IIIB • Study visits – assessments at 0, 6, and 12 months: - Neurocognitive (Leiter) and parental rating assessments (ABAS II) - Timed functional motor tests - Standard laboratory assessments - Serum/leukocyte NAGL

  14. Slide 14: Phase 1/2 Trial Expansion for MPS IIIA

    Phase 1/2 Trial Expansion for MPS IIIA • Phase 1/2 ABO-102 (scAAV-SGSH) open-label, dose- escalation clinical trials - Cohort 1: 5 X 1012 vg/kg (n=3 subjects) - Cohort 2: 1 X 1013 vg/kg (n=3 subjects) - Cohort 3: 3 x 1013 vg/kg (5 patients treated) - to enroll total of 6-9 additional patients at thr

  15. Slide 15: Biopotency: Reduction in CSF HS

    Biopotency: Reduction in CSF HS Dose and time-dependent reduction of CSF heparan sulfate (HS) fragments indicate ABO-102 crosses the blood-brain barrier Day 30 Day 180 Day 360 0% -10% -25.8% -20% Heparan sulfate (HS) % Reduction in CSF Cohort 1 -48.8% -30% -58.7% Cohort 2 -57.1% -40% Cohort 3 -50% -

  16. Slide 16: Biopotency: Dose Escalation Enhances Reduction in Urine HS

    Biopotency: Dose Escalation Enhances Reduction in Urine HS Day 30 Day 60 Day 90 Day 180 Day 360 0% -10% -29.2% -29.2% -20% -54.0% -54.2% -30% -64.2% -64.2% -63.1% -65.2% % Reduction in Urine Heparan sulfate (HS) -40% -50% -55.0% -60% Cohort 1 -70% -73.4% Cohort 2 -80% Cohort 3 -91.9% -90% -94.9% -10

  17. Slide 17: Biophysical: Liver Volume Change After Treatment

    Biophysical: Liver Volume Change After Treatment % Normal Liver Volume Cohort 1 Subject A Subject B Subject C Day 30 Day 180 Day 360 Screening 225% 202% 225% 0% Day 30 183% 174% 157% -10% Day 180 147% 150% 119% -31% Day 360 147% 149% 116% -20% -53% Absolute % Change -30% % Normal Liver Volume -46% C

  18. Slide 18: Neurocognitive: Initial Benefit Evidence in Leiter Assessment

    Neurocognitive: Initial Benefit Evidence in Leiter Assessment Cohort 1 Cohort 2 NHS C1 age equivalent group (n=8): • age 4.2-6.4 years • Mean decline for 12 observations over six month periods NHS C2 age equivalent group (n=3): • age 2.1-2.8 years *Cohort 1 (n=2): • Mean decline for 3 observations o

  19. Slide 19: Neurocognitive: Vineland Adaptive Behavior Assessment

    Neurocognitive: Vineland Adaptive Behavior Assessment Cohort 1 Cohort 2 NHS C1 age equivalent group (n=9): NHS C2 age equivalent group (n=3): • age 4.2-6.4 years • age 2.1-2.8 years • Mean decline for 12 observations over six • Mean decline for 3 observations over six month periods month periods 19

  20. Slide 20: Deep Brain Architecture: Cortical Thickness, Corpus Callosum, Thalamus, Putamen

    Deep Brain Architecture: Cortical Thickness Average, Corpus Callosum, Thalamus and Putamen Volume • Corpus callosum infarction can cause cognitive dysfunction, accompanied by different degrees of decline in visuospatial abilities, attention and calculating abilities. 1 • Total cortical thickness los

  21. Slide 21: Summary of ABO-102 Clinical Data

    Summary of ABO-102 Clinical Data • Dosing of ABO-102 has demonstrated time-dependent and dose-dependent responses • Evidence for biopotency and biophysical clinical benefit - Decreased CSF GAGs (HS) fragments - Decreased urinary GAGS (HS) - Reduction of liver volumes • Early positive signals of neur

  22. Slide 22: ABO-101 for Treatment of MPS IIIB

    ABO-101 for Treatment of MPS IIIB – Phase 1/2 open-label, dose- Enzyme Activity 30-days post infusion escalation clinical trials • Two dose cohorts of n=12-15 subjects via intravenous injection • Cohort 1: 2 X 1013 vg/kg (n=3 subjects) • Cohort 2: 5 X 1013 vg/kg (n=9-12 subjects) • Clinical sites: U

  23. Slide 23: MPS IIIB Phase 1/2 Trial: Demonstration of Safety and Efficacy

    MPS IIIB Phase 1/2 Trial: Demonstration of Safety and Efficacy Screening Day 30 0% 0% % Decrease in CSF Heparan -10% from baseline (pmol/mL) Decreases of Heparan Sulfate at 30 -20% days post infusion (n=1) in: -50% sulfate • Plasma -30% • CSF -40% • Urine -50% Cohort 1 (n=1) -60% Screening 0% Day 7

  24. Slide 24: Gene & Cell Therapy Manufacturing

    Gene & Cell Therapy Manufacturing The Elisa Linton Center for Rare Disease Therapies 24

  25. Slide 25: Cell & Gene Therapy Manufacturing Strategy

    Cell & Gene Therapy Manufacturing Strategy A combination strategy to ensure long-term continuous supply for domestic and international clinical trials as well as commercial demand. • Utilizing established Contract Manufacturing Organizations (CMOs) • Nationwide Children’s Hospital, Stanford, and CMO

  26. Slide 26: Staged Approach to CMC Development

    Staged Approach to CMC Development • Total 25,000 ft² GMP manufacturing to meet projected commercial demand o Stage 1: ~5,000 ft² facility – “The Elisa Linton Center for Rare Disease Therapies” - EB-101 / ABO-102 / AIM o Stage 2: 20,000 ft² facility – initiated • CMOs to be used for process developm

  27. Slide 27: Batten Disease Next Generation AAV Vector Platform

    Batten Disease Metabolic pre-clinical programs Next Generation AAV Vector Platform AIM™ chimeric vectors targeting multiple organs and tissues 27

  28. Slide 28: AIM Vector Platform

    AIM Vector Platform AIM™ Vector Platform • Next generation AAV viral vector platform to target CNS, skin, muscle, liver and other tissues • Over 60 novel AAV Capsids - multiple tissue platforms Key Advantages of AIM™  Increased gene delivery efficiency with new tissue tropisms  Potential for redos

  29. Slide 29: Directed Capsid Evolution: Enhanced & Specific Tissue Tropism

    Directed Capsid Evolution: Enhanced & Specific Tissue Tropism 29

  30. Slide 30: AIM Vectors Demonstrate Increased Tissue Specificity

    AIM Vectors Demonstrate Increased Tissue Specificity Cervical Cord Lumbar Cord TRANSDUCTION EFFICIENCY, % TRANSDUCTION EFFICIENCY, % 2500 180 160 2000 140 168 1914 120 1500 100 1000 80 100 60 85 500 40 100 20 43 9 255 25 287 216 0 31 3 0 0 AAV 303 101 102 103 104 212 AAV 303 101 102 103 104 212 Brai

  31. Slide 31: ABO-202: CLN1 Disease – Infantile Batten

    ABO-202: CLN1 Disease – Infantile Batten Clinical trial to commence in 2018 • Autosomal recessive (inherited) mutation in the CLN1 gene • Diagnosed between ages 6 months and 2 years – with early death before age 5 • Preclinical work shows promising efficacy in INCL mice after delivery of a functioni

  32. Slide 32: ABO-201: CLN3 Disease – Juvenile Batten

    ABO-201: CLN 3 Disease – Juvenile Batten • CLN3 - Autosomal recessive (inherited) mutation in the CLN3 gene - Initially presents as blindness, progressing to behavioral issues, sleep disturbances, seizures, cognitive loss, motor abnormalities, premature death (late teens-early 20s) - Neurodegenerati

  33. Slide 33: Financial Overview

    Financial Overview Cash $137.8 million (at December 31, 2017) Net Cash Used in Operations $22.9 million (Twelve Months Ended December 31, 2017) Primary Common Shares Out 46.9 million (at December 31, 2017) 33

  34. Slide 34: Management and SAB

    Management and SAB Management Team • Carsten Thiel, Ph.D. - Chief Executive Officer • Timothy J. Miller, Ph.D. - President, Chief Scientific Officer • Jeffrey B. Davis - Chief Operating Officer • Juan Ruiz, M.D., Ph.D. - Chief Medical Officer • Stephen B. Thompson - Chief Accounting Officer • S. Kay

Abeona Therapeutics — Investor Presentation (April 2018) on 6ix